Pembrolizumab/Lenvatinib Combo Achieves Promising Responses in Anaplastic Thyroid Cancer
Christine Dierks, MD, discusses the results from the prospective phase 2 ATLEP study of lenvatinib in combination with pembrolizumab as treatment of patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.
Christine Dierks, MD, senior physician, University Hospital Freilburg, Germany, discusses the results from the prospective phase 2 ATLEP study of lenvatinib (Lenvima) in combination with pembrolizumab (Keytruda) as treatment of patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.
In this study, 4 out of 8 patients achieved a complete response (CR) with the combination, and of the 4 patients, 3 are still alive, says Dierks. All patients who achieved a CR had anaplastic thyroid carcinoma.
Biomarkers observed in this small cohort of good responses included high PD-L1 status and increased tumor mutational burden. The median progression-free survival was 17.75 months, and the median overall survival is 19 months. The longest duration of treatment was 40 months in 1 patient, and 3 patients remained alive, receiving pembrolizumab monotherapy as the lenvatinib is stopped on the study when responses are achieved.
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
